)
Visual
test
Vor Biopharma
Vor Biopharma (VOR) investor relations material
Vor Biopharma Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary29 Jan, 2026
Company overview and business model
Clinical-stage biopharmaceutical company developing telitacicept, a novel fusion protein targeting autoimmune diseases by inhibiting BAFF and APRIL signaling pathways.
Holds exclusive rights to develop and commercialize telitacicept outside Greater China; RemeGen retains rights in Greater China.
Telitacicept is approved in China for several autoimmune indications and is in a global Phase 3 trial for generalized myasthenia gravis (gMG).
Broader development plans include additional autoantibody-driven diseases, such as Sjögren's disease, with significant unmet need.
Financial performance and metrics
Raised $150 million in gross proceeds from a private placement of 13,876,032 shares at $10.81 per share in December 2025.
As of January 26, 2026, 41,519,840 shares of common stock were outstanding.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.
Responsible for registration expenses; selling stockholders bear their own broker commissions.
Telitacicept global indication strategy
Mitigate going concern doubt
Impact of large shareholder share resales
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebARES
AUM climbed 29% to $622.5B, with record fundraising, earnings, and a 20% dividend increase. - 5 FebFR
FFO per share rose 11.7% in 2025, with strong leasing and a 12.4% dividend increase. - 5 FebBTU
Centurion Mine launch and strong cash flow position drive higher 2026 met coal volumes and returns. - 5 Feb033780
Record earnings, robust shareholder returns, and global expansion mark 2025; moderate growth targeted for 2026. - 5 FebWST
Integrated PFS system accelerates development, reduces risk, and simplifies compliance. - 5 FebCMS
2025 adjusted EPS up 8%+ to $3.61, 2026 guidance raised, $24B plan drives growth. - 5 FebCHILE
2025 net income reached CLP 1,192,262 million, with strong capital and digital-driven growth ahead. - 5 FebORLY
Record 2025 results with 6% sales and 10% EPS growth, plus strong 2026 outlook. - 5 FebOWL
AUM surpassed $300 billion in 2025 amid record fundraising and double-digit earnings growth. - 5 Feb035760
Operating profit doubled YOY in Q4 2025, led by global content and platform growth.
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
Vor Biopharma
Next Vor Biopharma earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for blood cancers. The company's approach combines cell and genome engineering to create therapies that target and treat hematological malignancies. Vor's proprietary platform primarily involves engineering hematopoietic stem cells (HSCs) to enhance their compatibility with targeted therapies. The lead product candidate, an engineered HSC known as tremtelectogene empogeditemcel (trem-cel), is currently in clinical trials for the treatment of acute myeloid leukemia (AML). Vor is also working on additional therapies that involve chimeric antigen receptor T-cells (CAR-T) and antibody-drug conjugates to further expand its cancer treatment portfolio. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage